Maria Angeles Sala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Angeles Sala has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Mariano Provencio
Puerta de Hierro University Hospital, Majadahonda, Spain
16 shared publications - Byoung Chul Cho
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea
15 shared publications - Chong Ming Yeo
Tan Tock Seng Hosp, Dept Med Oncol, Singapore, Singapore
15 shared publications - Christian Britschgi
Department of Medical Oncology and Hematology, Cantonal Hospital Winterthur, Winterthur, Switzerland
15 shared publications - Enric Carcereny
Catalan Institute of Oncology – Badalona, B-ARGO Group, Barcelona, Spain
15 shared publications - Ernest Nadal
Department of Medical Oncology, Institut Català d’Oncologia (ICO), IDIBELL, Bellvitge Healthcare Campus, L’Hospitalet de Llobregat, Barcelona, Spain
15 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
Socioeconomic disparities in sarcoma diagnosis, expert center access, and advocacy group awareness: a multicenter study in Southern Europe
Background: Management of sarcoma in expert centers (SECs) improves outcomes, and patient advocacy groups provide information, support, and representation of patients’ needs; however, access to both remains uneven. We aimed to identify factors associated with patient referral and advocacy group awareness in Spain and Portugal, 2 universal healthcare systems with distinct sarcoma pathways. Materials and Methods: Between April and December 2023, we conducted a survey-based study of adults with sarcoma under active treatment or follow-up across 9 Spanish hospitals (5 SECs) and one Portuguese hospital. Sociodemographic and clinical data, referral patterns, and advocacy group awareness/contact were analyzed. Results: A total of 415 patients were included (Spain, n = 365; Portugal, n = 50). In Spain, lower income (odds ratio [OR] 2.38; 95% CI, 1.16-5.03) was associated with longer diagnostic delays. Rural residence (OR 3.48; 1.79-7.04) and longer diagnostic delays (OR 2.41; 1.26-4.66) were associated with referral to other hospitals. Cancer advocacy group awareness was lower among patients with lower income (OR 0.38; 0.17-0.81) and higher with longer diagnostic delays (OR 2.08; 1.05-4.25). Sarcoma-specific advocacy group awareness was generally low (20%) but higher with university education (OR 4.27; 1.56-12.35). Few patients contacted cancer (14%) or sarcoma-specific groups (7%); contact was more frequent with longer diagnostic delays (OR 2.27; 1.11-4.63) or symptomatic presentation (OR 2.50; 1.04-5.97). Compared with the Portuguese cohort, Spanish patients were referred less frequently and had greater awareness of advocacy groups. Conclusion: Socioeconomic disparities affect sarcoma diagnosis, referral, and advocacy group engagement, even within universal healthcare systems. Equity-oriented care requires timely SEC referral and advocacy group visibility.
- 7 September 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
Open AccessSocioeconomic disparities in sarcoma diagnosis, expert center access, and advocacy group awareness: a multicenter study in Southern Europe
Background: Management of sarcoma in expert centers (SECs) improves outcomes, and patient advocacy groups provide information, support, and representation of patients’ needs; however, access to both remains uneven. We aimed to identify factors associated with patient referral and advocacy group awareness in Spain and Portugal, 2 universal healthcare systems with distinct sarcoma pathways. Materials and Methods: Between April and December 2023, we conducted a survey-based study of adults with sarcoma under active treatment or follow-up across 9 Spanish hospitals (5 SECs) and one Portuguese hospital. Sociodemographic and clinical data, referral patterns, and advocacy group awareness/contact were analyzed. Results: A total of 415 patients were included (Spain, n = 365; Portugal, n = 50). In Spain, lower income (odds ratio [OR] 2.38; 95% CI, 1.16-5.03) was associated with longer diagnostic delays. Rural residence (OR 3.48; 1.79-7.04) and longer diagnostic delays (OR 2.41; 1.26-4.66) were associated with referral to other hospitals. Cancer advocacy group awareness was lower among patients with lower income (OR 0.38; 0.17-0.81) and higher with longer diagnostic delays (OR 2.08; 1.05-4.25). Sarcoma-specific advocacy group awareness was generally low (20%) but higher with university education (OR 4.27; 1.56-12.35). Few patients contacted cancer (14%) or sarcoma-specific groups (7%); contact was more frequent with longer diagnostic delays (OR 2.27; 1.11-4.63) or symptomatic presentation (OR 2.50; 1.04-5.97). Compared with the Portuguese cohort, Spanish patients were referred less frequently and had greater awareness of advocacy groups. Conclusion: Socioeconomic disparities affect sarcoma diagnosis, referral, and advocacy group engagement, even within universal healthcare systems. Equity-oriented care requires timely SEC referral and advocacy group visibility.
- Open Access
- 12 August 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 56
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain
- 12 August 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 56
Open AccessIncidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in Spain
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S1. Consort diagram.
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S1. Consort diagram.
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix S1 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
List of ETOP 10-16 BOOSTER collaborators
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix S1 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
List of ETOP 10-16 BOOSTER collaborators
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S9. Overall survival for the N=136 patients constituting the biomarker analysis cohort, by baseline mutational status of (A) EGFR T790M (B) TP53.
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S9. Overall survival for the N=136 patients constituting the biomarker analysis cohort, by baseline mutational status of (A) EGFR T790M (B) TP53.
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S3. EGFR T790M mutational status (MD/MND) by treatment arm at baseline (N=136), week 9 (N=110) and progression (N=65).
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S3. EGFR T790M mutational status (MD/MND) by treatment arm at baseline (N=136), week 9 (N=110) and progression (N=65).
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S5. Boxplot of EGFR T790M MAF distribution at baseline (N=136), week 9 (N=110) and progression (N=65) by treatment arm.
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S5. Boxplot of EGFR T790M MAF distribution at baseline (N=136), week 9 (N=110) and progression (N=65) by treatment arm.
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Data from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Purpose:The ETOP 10-16 BOOSTER study was a randomized phase II trial of osimertinib and bevacizumab therapy versus osimertinib therapy in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistance to osimertinib and bevacizumab have not been described previously.Experimental Design:Next-generation sequencing (Guardant360) was conducted in serial plasma samples. The association between ctDNA and efficacy outcomes was explored, and molecular alterations at progression were described.Results:A total of 136 patients (88% of 155 randomized) had plasma samples at baseline (68 per arm), 110 (71%) at week 9, and 65 (42%) at progression. In a multivariable model for progression-free survival (PFS), the treatment effect was found to differ by smoking status (interaction P = 0.046), with the effect of smoking also differing by baseline EGFR T790M (interaction P = 0.033), whereas both TP53 at baseline and the tissue EGFR exon 21 L858R mutation were significantly associated with worse PFS outcome. Smokers (current/former) without baseline EGFR T790M showed a significant improvement in PFS under combination treatment, albeit with small numbers (P = 0.015). Week-9 EGFR T790M clearance was associated with improved PFS in the osimertinib arm (P = 0.0097). Acquired EGFR C797S mutations were detected in 22% and 13% of patients in the combination and osimertinib arms, respectively.Conclusions:The differential effect of treatment by smoking was not explained by TP53 mutations or other molecular alterations examined. Molecular mechanisms of acquired resistance were detected, but no novel molecular alterations were identified in the combination arm.
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Purpose:The ETOP 10-16 BOOSTER study was a randomized phase II trial of osimertinib and bevacizumab therapy versus osimertinib therapy in patients with an acquired EGFR T790M mutation. The mechanisms of acquired resistance to osimertinib and bevacizumab have not been described previously.Experimental Design:Next-generation sequencing (Guardant360) was conducted in serial plasma samples. The association between ctDNA and efficacy outcomes was explored, and molecular alterations at progression were described.Results:A total of 136 patients (88% of 155 randomized) had plasma samples at baseline (68 per arm), 110 (71%) at week 9, and 65 (42%) at progression. In a multivariable model for progression-free survival (PFS), the treatment effect was found to differ by smoking status (interaction P = 0.046), with the effect of smoking also differing by baseline EGFR T790M (interaction P = 0.033), whereas both TP53 at baseline and the tissue EGFR exon 21 L858R mutation were significantly associated with worse PFS outcome. Smokers (current/former) without baseline EGFR T790M showed a significant improvement in PFS under combination treatment, albeit with small numbers (P = 0.015). Week-9 EGFR T790M clearance was associated with improved PFS in the osimertinib arm (P = 0.0097). Acquired EGFR C797S mutations were detected in 22% and 13% of patients in the combination and osimertinib arms, respectively.Conclusions:The differential effect of treatment by smoking was not explained by TP53 mutations or other molecular alterations examined. Molecular mechanisms of acquired resistance were detected, but no novel molecular alterations were identified in the combination arm.
- Open Access
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S10. Overall survival by EGFR T790M mutational status at week 9 (N=106) - landmark analysis (post 9-week time).
- 15 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Supplementary Figure S10. Overall survival by EGFR T790M mutational status at week 9 (N=106) - landmark analysis (post 9-week time).